Dissolution studies of 3D-printed inserts in a novel biopharmaceutical bladder model.

[1]  J. Breitkreutz,et al.  Development and optimization of sustained-release drug-loaded intravesical inserts via semi-solid micro-extrusion 3D-printing for bladder targeting. , 2022, International journal of pharmaceutics.

[2]  J. Siepmann,et al.  How agarose gels surrounding PLGA implants limit swelling and slow down drug release. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[3]  A. Gazzaniga,et al.  Intravesical drug delivery approaches for improved therapy of urinary bladder diseases , 2021, International journal of pharmaceutics: X.

[4]  Sarah J Trenfield,et al.  Stereolithography (SLA) 3D printing of a bladder device for intravesical drug delivery. , 2021, Materials science & engineering. C, Materials for biological applications.

[5]  Eneko Larrañeta,et al.  Development of a Biodegradable Subcutaneous Implant for Prolonged Drug Delivery Using 3D Printing , 2020, Pharmaceutics.

[6]  F. Pisano,et al.  Updates on intravesical therapy. , 2019, Current opinion in urology.

[7]  E. Bellin,et al.  Prevalence, Risk Factors, and Treatment for Overactive Bladder in a Racially Diverse Population. , 2019, Urology.

[8]  S. Pandini,et al.  Retentive device for intravesical drug delivery based on water‐induced shape memory response of poly(vinyl alcohol): design concept and 4D printing feasibility , 2019, International journal of pharmaceutics.

[9]  Cindy Alejandra Gutiérrez-Valenzuela,et al.  Mathematical modeling and parametrical analysis of the temperature dependency of control drug release from biodegradable nanoparticles , 2019, RSC advances.

[10]  J. Breitkreutz,et al.  Dissolution testing of oral film preparations: Experimental comparison of compendial and non‐compendial methods , 2019, International journal of pharmaceutics.

[11]  S. Kielb,et al.  Female Voiding Dysfunction and Urinary Incontinence. , 2017, The Medical clinics of North America.

[12]  Lei Shang,et al.  Long-term floating control-released intravesical preparation of 5-fluorouracil for the local treatment of bladder cancer , 2017, Drug development and industrial pharmacy.

[13]  L. Cardozo,et al.  Research and Reports in Urology Dovepress Novel Targeted Bladder Drug-delivery Systems: a Review , 2022 .

[14]  Jay C. Sy,et al.  Single compartment drug delivery. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[15]  J. Breitkreutz,et al.  Lipid-based intravesical drug delivery systems with controlled release of trospium chloride for the urinary bladder. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[16]  K. Burgio,et al.  Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. , 2012, The Journal of urology.

[17]  M. Chancellor,et al.  Intravesical therapy for lower urinary tract symptoms , 2012 .

[18]  Juergen Siepmann,et al.  Modeling of diffusion controlled drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[19]  S. Stanton,et al.  The management of overactive bladder syndrome , 2012, BMJ : British Medical Journal.

[20]  X. Lou,et al.  The Influence of Temperature and Drug Concentrations Prednisolone in NIPAAm Copolymer , 2012 .

[21]  Nicholas A Peppas,et al.  Higuchi equation: derivation, applications, use and misuse. , 2011, International journal of pharmaceutics.

[22]  Todd L. Cecil,et al.  FIP/AAPS Joint Workshop Report: Dissolution/In Vitro Release Testing of Novel/Special Dosage Forms , 2011, AAPS PharmSciTech.

[23]  J. Benner,et al.  Patient‐reported reasons for discontinuing overactive bladder medication , 2010, BJU international.

[24]  S. Ubee,et al.  Medical management of overactive bladder , 2010, Indian journal of urology : IJU : journal of the Urological Society of India.

[25]  J. Stolzenburg,et al.  Anatomy of the Lower Urinary Tract , 2010 .

[26]  K. Coyne,et al.  The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well‐being in men and women: results from the EPIC study , 2008, BJU international.

[27]  C. Kelleher,et al.  It's just the worry about not being able to control it! A qualitative study of living with overactive bladder. , 2008, British journal of health psychology.

[28]  Cynthia K. Brown,et al.  FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms , 2008, AAPS PharmSciTech.

[29]  R. Evans.  Intravesical therapy for overactive bladder , 2006 .

[30]  Christos Reppas,et al.  Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.

[31]  W. Stewart,et al.  Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.

[32]  P. Abrams,et al.  How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study , 2001, BJU international.

[33]  C. Fowler,et al.  Intravesical treatment of overactive bladder. , 2000, Urology.

[34]  J. Wyndaele.  The normal pattern of perception of bladder filling during cystometry studied in 38 young healthy volunteers. , 1998, The Journal of urology.

[35]  G. L. Robertson,et al.  Diabetes insipidus. , 1995, Endocrinology and metabolism clinics of North America.

[36]  N. Peppas,et al.  A simple equation for the description of solute release. III. Coupling of diffusion and relaxation , 1989 .

[37]  Nicholas A. Peppas,et al.  A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs , 1987 .

[38]  D. Musher,et al.  Urease. The primary cause of infection-induced urinary stones. , 1976, Investigative urology.

[39]  T. Higuchi.  MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES. , 1963, Journal of pharmaceutical sciences.